Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment

By Mark C. Via

FIGURES

Figure 1.1. Structure of Rabbit Immunoglobulin G
Figure 2.1. Monoclonal Antibody Production
Figure 2.2. Antibody Engineering
Figure 2.3. Engineered Forms of Antibodies
Figure 2.4. Benefits and Limitations of Different Production Systems for Recombinant Proteins
Figure 4.1. Number of Therapeutic Monoclonal Antibodies Entering Clinical Study per Year, 1980–2004

TABLES

Table 3.1. FDA-Approved Therapeutic Monoclonal Antibodies
Table 3.2. Unconjugated Monoclonal Antibodies in Clinical Trials for Cancer
Table 3.3. Conjugated Monoclonal Antibodies in Clinical Trials for Cancer
Table 3.4. Monoclonal Antibodies in Clinical Trials for Immunological Diseases
Table 3.5. Monoclonal Antibodies in Clinical Trials for Infectious Diseases
Table 3.6. Monoclonal Antibodies in Clinical Trials for Cardiovascular Diseases
Table 3.7. Other Therapeutic Monoclonal Antibodies in Clinical Development
Table 4.1. Worldwide Sales of Therapeutic Monoclonal Antibodies, 2005 and 2006
Table 4.2. Estimated New Cancer Cases in the United States, Total and Selected Types, 2007

APPENDIX FIGURES

Figure 1A. Respondents by Sector
Figure 2A. Focus of Respondents’ Organizations
Figure 3A. Professional Responsibilities of Respondents
Figure 4A. Changes in mAb Pipelines
Figure 5A. Magnitude of Increase in mAb Pipelines
Figure 6A. Recent Changes in Level of Activity Related to mAbs
Figure 7A. Future Changes in Level of Activity Related to mAbs
Figure 8A. Rate of New mAb Approvals
Figure 9A. Challenges to mAb Development
Figure 10A. Key Technologies
Figure 11A. Future Improvements to mAbs
Figure 12A. Relevant Disease Areas